CSIMarket
 


Sangamo Therapeutics Inc   (SGMO)
Other Ticker:  
 

Cumulative Sangamo Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

SGMO's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SGMO Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -57.27 % -60.38 % -55.17 % -51.2 % -12.65 %
Y / Y Cash & cash equivalent Growth -83.72 % -81.98 % -54.67 % -35.37 % -26.27 %
Quick Ratio for Trailing Twelve Months Period 2.17 2.51 2.72 2.7 2.59
Total Ranking # 470 # 844 # 873 # 962 # 1140
Seq. Current Liabilities Growth -1.55 % -9.87 % -7 % -48.22 % -8.7 %
Seq. Cash & cash equivalent Growth -20.01 % -60.51 % -30.33 % -26.02 % -11.46 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite year on year decrease in Sangamo Therapeutics Inc 's average Current Liabilities to $48 millions, Quick Ratio for Trailing Twelve Months Period to 2.17 below company average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Sangamo Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about SGMO
Quick Ratio SGMO in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 54
Sector # 306
S&P 500 # 800


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.53 6.63 2.17
(Dec 31 2016)   (Dec 31 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Vir Biotechnology Inc   5.87 
Dyadic International Inc  5.85 
Alector Inc   5.66 
X4 Pharmaceuticals Inc  5.60 
Editas Medicine Inc   5.59 
Biontech Se  5.39 
Denali Therapeutics Inc   5.27 
Omega Therapeutics Inc   5.24 
Senti Biosciences Inc   5.22 
Iovance Biotherapeutics Inc   5.17 
Opthea Limited  5.07 
Miromatrix Medical inc   5.05 
Twist Bioscience Corporation  5.00 
Ocugen Inc   4.94 
Gritstone Bio Inc   4.85 
Cognition Therapeutics inc   4.83 
Prime Medicine Inc   4.80 
Molecular Partners Ag  4.79 
Fresh Tracks Therapeutics Inc   4.78 
Recursion Pharmaceuticals Inc   4.75 
Adaptive Biotechnologies Corporation  4.47 
Argenx se  4.42 
Sutro Biopharma Inc   4.38 
Fennec Pharmaceuticals Inc   4.36 
Finch Therapeutics Group Inc   4.32 
Poseida Therapeutics Inc   4.28 
Adverum Biotechnologies Inc   4.25 
Polarityte Inc   4.21 
In8bio Inc   4.20 
Inmune Bio Inc   4.08 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com